··

{"@context":"https://schema.org","@graph":[{"@type":"Drug","name":"Retatrutide","alternateName":"LY3437943","description":"Triple GIP/GLP-1/glucagon receptor agonist studied in metabolic research.","legalStatus":"Research use only","drugClass":"Triple agonist (GIP/GLP-1/glucagon)","url":"https://longeva.bio/ua/wiki/retatrutide","mainEntityOfPage":"https://longeva.bio/ua/wiki/retatrutide"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Wiki","item":"https://longeva.bio/wiki"},{"@type":"ListItem","position":2,"name":"GLP-1 / GIP","item":"https://longeva.bio/wiki?category=glp-1-gip"},{"@type":"ListItem","position":3,"name":"Retatrutide","item":"https://longeva.bio/ua/wiki/retatrutide"}]}]}

GLP-1 / GIP · RESEARCH USE ONLY

Retatrutide

Triple agonist (GIP/GLP-1/glucagon) · LY3437943

Overview

Retatrutide (LY3437943) is a synthetic peptide studied in preclinical and clinical metabolic research as a triple agonist of the GIP, GLP-1 and glucagon receptors.

Mechanism

Simultaneous activation of three incretin and glucagon pathways. Refer to peer-reviewed literature for pharmacology and study data.

Provided strictly for research purposes. Not for human use. No dosing guidance.

Інформація надається виключно з науково-дослідною метою. Не для застосування людиною. Без рекомендацій щодо дозування.

Пов'язані речовини

Semaglutide